Early detection of prostate cancer remains a major clinical challenge due to the lack of reliable biomarkers, despite the disease being highly treatable when caught in its early stages. Now, ...

Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear. Scientists at the University of Cambridge, led by Professor Ljiljana Fruk and ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. To confirm the diagnosis, biopsies are required. A team of researchers has now ...

Singapore, 13 May 2025 – Urological cancers – namely bladder, kidney, and prostate cancers – share several risk factors and individuals at risk for one may be at higher risk for developing another.

A remarkable scientific advancement could transform how prostate cancer is detected in men around the world. Researchers have developed a groundbreaking urine test that offers significant advantages ...

Prostate cancer is one of the most common and deadly forms of cancer in men, yet early detection remains a major challenge. That difficulty lies in how subtle the disease can be in its earliest stages ...

-Only MCED test to use a urine sample collected at home instead of blood draw. -Only MCED to detect stage I/II cancers with 97% sensitivity and 97% specificity. -Offered as a laboratory-developed test ...